Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Novo Nordisk (NVO - Analyst Report), carrying a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today ...
ZACKS · 2 minutes ago
NEW YORK (TheStreet) -- Bristol-Myers Squibb's (BMY - Get Report) Empliciti drug has received approval from the Food and Drug Administration for priority review. This drug is used to treat multiple myeloma …
The Street · 1 day ago
Pharmaceutical giant Bristol-Myers Squibb Co (NYSE:BMY) stock has performed modestly well year-to-date (YTD), with some steep increases offsetting a few declines. Overall, the stock is expected to continue rising … · 8/25/2015
More from Bing News
Investors in Bristol-Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the October 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BMY options …
NASDAQ · 8/24/2015
Bristol-Myers Squibb (NYSE:BMY) has been assigned a consensus rating of “Hold” from the twenty analysts that are currently covering the firm, MarketBeat.Com reports. One research analyst has rated the stock with a sell rating, ten have given a hold ... · 1 day ago
Bristol-Myers boasts a robust pipeline. The successful development of the pipeline would boost the stock. Bristol-Myers has a dividend yield of 2.54%. Aug 21 – 25: -8.2% Aug 26 – 28: 4.6% AT&T, Inc. T is the second largest provider of wireless services ...
Yahoo Finance · 19 minutes ago
Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “hold” rating reissued by equities research analysts at Jefferies Group in a report issued on Thursday, ARN reports. They presently have a $59.00 price target on the biopharmaceutical company’s stock.
Ticker Report · 8/27/2015
BMY closed Friday's trading at $60.61, down 0.35%. Stellar Biotechnologies Inc. (SBOTF.OB) (KLH.V) has announced a 1 for 10 reverse stock split in preparation for the proposed uplisting to NASDAQ capital market.
Realtime Business News · 8/31/2015
BMY) in a research report released on Tuesday, ARN reports. The firm currently has a $75.00 price objective on the biopharmaceutical company’s stock. Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 2.
Mideast Times · 8/22/2015
I consider BMY, DIS and WFC to be "Quality Stocks" as I have defined ... One other major factor is the statistical fact that, historically, September is the worst month for stock gains. Combined with volatility overseas in China and other Asian markets ...
Seeking Alpha · 9/1/2015
Generation Portfolio

Bristol-Myers Squibb

Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-M…
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
Data from: Wikipedia · Freebase